Plus Therapeutics Secures AMA Approval For New CPT Code Supporting REYOBIQ Delivery In CNS Cancers

Plus Therapeutics, Inc. announced that the American Medical Association (AMA) CPT® Editorial Panel has approved a new Category III CPT code to track the use of convection-enhanced delivery (CED) in administering REYOBIQ for recurrent glioblastoma (rGBM) and pediatric brain cancer (PBC).

Category III CPT codes are designed to monitor emerging medical technologies and procedures, facilitating data collection that may support future reimbursement decisions and potential transition to permanent Category I codes. The newly approved code, X566T, covers stereotactic placement of brain infusion catheters for therapeutic delivery, including computerized planning and burr hole procedures. The code will be published on July 1, 2026, and will take effect for reporting on January 1, 2027.

“The approved Category III CPT code for convection-enhanced delivery of REYOBIQ in recurrent glioblastoma and pediatric brain cancer – the most prevalent malignant tumors of the brain and central nervous system – marks a major step in bringing market access for an innovative treatment targeting an aggressive and deadly disease resistant to conventional treatments. This milestone reflects the culmination of years of REYOBIQ development and represents an important advancement in our path to commercialization and reimbursement. With standardized REYOBIQ clinical use now tracked under the new CPT code, its utilization can be evaluated as a bridge to approval and broad adoption,” said Marc Hedrick MD, Plus Therapeutics President and CEO. “We remain focused on making strong clinical progress with REYOBIQ. We are on track to complete enrollment in our Phase 2 recurrent glioblastoma trial in 2026, followed by an end-of-Phase 2 meeting to align on pivotal trial design. In addition, we continue to expect first patient enrollment in our Phase 1 pediatric brain cancer trial in 2026.”

REYOBIQ (rhenium Re186 obisbemeda) is an investigational injectable radiotherapy formulated to deliver high-dose, targeted radiation directly to central nervous system (CNS) tumors. The therapy is designed to enhance precision while minimizing off-target exposure, potentially improving outcomes compared to currently available treatments.

Rhenium-186 is considered well-suited for CNS applications due to its short half-life, beta particle emissions that destroy cancer cells, and gamma emissions that enable real-time imaging. Through the use of CED, REYOBIQ aims to optimize localized drug distribution within brain tumors while maintaining a favorable safety profile.